
Akhil Santhosh
Apr 13, 2025, 18:24
Akhil Santhosh: First-Line Adagrasib and Pembrolizumab for Metastatic NSCLC
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“First line adagrasib + pembrolizumab for metastatic NSCLC with PDL1>50% and KRAS G12 C: Krystal 7 phase 2 study”
More posts featuring Akhil Santhosh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 07:23
Apr 15, 2025, 07:10
Apr 15, 2025, 07:04